Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | KAT2B | Q92831 | 9/20 | 0.59 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.59 |
| ▸ | BRD4 | O60885 | 8/20 | 0.58 |
| ▸ | BPTF | Q12830 | 7/20 | 0.51 |
| ▸ | CNR2 | P34972 | 3/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3250048 | 0.84 | KAT2B (0.63) | KAT2BBRD9BRD4BPTFCNR2 | |
| SCHEMBL9982965 | 0.79 | BPTF (0.68) | KDM4ERAB9ASMN1; SMN2KAT2BBRD9 | |
| SCHEMBL3247038 | 0.77 | KAT2B (0.65) | KAT2BBRD9BRD4BPTF | |
| SCHEMBL8243863 | 0.73 | RAB9A (0.91) | KDM4ERAB9ASMN1; SMN2CNR2 | |
| SCHEMBL9527777 | 0.73 | KAT2B (0.57) | SMN1; SMN2KAT2BBRD9BRD4BPTF | |
| SCHEMBL10366891 | 0.72 | SMN1; SMN2 (0.51) | KDM4ERAB9ASMN1; SMN2KAT2BBRD9 | |
| SCHEMBL7160804 | 0.72 | KAT2B (0.74) | KAT2BBRD9BRD4BPTF | |
| SCHEMBL9528713 | 0.72 | BRD4 (0.55) | KAT2BBRD9BRD4 | |
| SCHEMBL9527132 | 0.72 | KAT2B (0.49) | KAT2BBRD9BRD4BPTFCNR2 | |
| SCHEMBL22749223 | 0.72 | CNR2 (0.48) | KDM4ERAB9ASMN1; SMN2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2132188-B1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLEDINEDIONE AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-14 | — | — | EP | claimed |
| US-8586596-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| WO-2011159785-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-12-22 | — | — | WO | disclosed |
| US-20110306616-A1 | Novel Compounds as Cannabinoid Receptor Ligands | ABBOTT LABORATORIES (US) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306616-A1 | Novel Compounds as Cannabinoid Receptor Ligands | CNR1, CNR2, GPR18 | KDM4E 3114/4885RAB9A 866/4885SMN1; SMN2 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.